---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-23-000027"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2023-07-25T23:59:59+00:00"
generated_at: "2026-06-13T03:45:27.970889+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biogen Q2 revenue $2.46B (-5% YoY); launches LEQEMBI, announces net $700M cost savings by 2025

## Summary
- Q2 revenue $2,456M; GAAP EPS $4.07, non-GAAP EPS $4.02; EPS down 44% and 23% YoY respectively.
- Launched Alzheimer's drug LEQEMBI in U.S. during Q2.
- Fit for Growth program: ~$1B gross savings, ~$300M reinvested, net ~$700M by 2025; ~1,000 headcount reduction.
- TECFIDERA EU regulatory protection extended to Feb 2, 2025; new SPINRAZA data in SMA post gene therapy.
- Reaffirmed full-year 2023 guidance; R&D pipeline prioritization substantially complete.

## SEC filing metadata
- accession: 0000875045-23-000027
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2023-07-25T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504523000027/0000875045-23-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504523000027/biib-20230725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-23-000027
- JSON: https://secwatch.observer/filing/0000875045-23-000027.json
- Plain text: https://secwatch.observer/filing/0000875045-23-000027.txt

## Key facts
- Earnings Releases
  BIOGEN INC. reported second quarter 2023 results: revenue $2,456 million, EPS $4.07. Guidance reaffirmed.
  - Period: second quarter 2023
  - Revenue: $2,456 million
  - EPS: $4.07
  - Guidance: reaffirmed
  - Result: reported results
  source text: Biogen reports second quarter 2023 results and reaffirms full year 2023 guidance; LEQEMBI launched in the U.S. Second quarter revenue $2,456 million; GAAP diluted EPS $4.07; Non-GAAP diluted EPS $4.02
  evidence_url: https://www.sec.gov/Archives/edgar/data/875045/000087504523000027/0000875045-23-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.